EMA Authorised: Irbesartan/Hydrochlorothiazide Teva (irbesartan;hydrochlorothiazide) — Teva B.V.

View source ↗

Summary

The European Medicines Agency authorised a fixed-dose combination of irbesartan and hydrochlorothiazide (Irbesartan/Hydrochlorothiazide Teva) for hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Irbesartan/Hydrochlorothiazide Teva (irbesartan/hydrochlorothiazide)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Teva B.V.. Decision date: 15/01/2026